Biotinylated Human BTN3A2 Protein
Catalog No: BTN3A2-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Biotinylated Human BTN3A2 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Gln30-Trp248 (UniProt accession: P78410-1).
Product Details
- Molecular Aliases
- BT3.2; BTF3; BTF4; BT3.3; BTN3A2; FLJ40011; BTN3.2; CD277
- Protein Length
- Gln30-Trp248
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 26.5 kDa. Due to glycosylation, the protein migrates to 30-38 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human BTN3A2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Background
BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial ovarian cancer (HG-EOC). In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with better outcome. In contrast, high CD206 /CD68 expression is associated with high risk of disease progression.
References
- Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, Madore J, Delvoye N, Mes-Masson AM, Provencher DM, Cailhier JF. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One. 2012;7(6):e38541. doi: 10.1371/journal.pone.0038541. Epub 2012 Jun 7. PMID: 22685580; PMCID: PMC3369854.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.